Newsroom

Bausch & Lomb GP Materials Receive Expanded FDA Post-Surgical Indications

Boston® XO®, EO® and ES® Gas Permeable Contact Lenses Receive Clearance for Use Following Penetrating Keratoplasty or Refractive Surgeries

FOR RELEASE THURSDAY, FEBRUARY 23, 2006

ATLANTA - The U.S. Food and Drug Administration has cleared an expanded post-surgical indication for Bausch & Lomb's Boston XO® (hexafocon A), Boston EO® (enflufocon B) and Boston ES ® (enflufocon A), gas permeable (GP) contact lenses for use in post-surgical situations following penetrating keratoplasty or refractive surgery.

The Boston XO, EO and ES GP contact lenses are indicated for the daily wear correction of refractive ametropia including: myopia, hyperopia, astigmatism and presbyopia in phakic and aphakic individuals with non-diseased eyes. The expanded indications now allow for these lenses to be prescribed in non-diseased eyes that require a rigid contact lens for the management of irregular corneal conditions such as keratoconus, Pellucid Marginal Degeneration (PMD), or following penetrating keratoplasty or refractive (e.g., LASIK) surgery.

The announcement was made at the SECO International 2006 optometric educational meeting held here until Feb. 26. Bausch & Lomb currently produces the Boston ES, EO and XO materials as lens buttons and Authorized Boston Manufacturers process the buttons into finished contact lenses according to the eye care practitioner's prescription.

These new lens designs must be cleaned and disinfected using an FDA-approved chemical disinfection system for gas permeable lenses, such as Bausch & Lomb's Boston SIMPLUS^TM Multi-Action Solution or Boston Advance^TM .

For more information about these specific GP lens materials, visit www.bausch.com .

Bausch & Lomb is the eye health company, dedicated to perfecting vision and enhancing life for consumers around the world. Its core businesses include soft and rigid gas permeable contact lenses and lens care products, and ophthalmic surgical and pharmaceutical products. The Bausch & Lomb name is one of the best known and most respected healthcare brands in the world. Founded in 1853, the Company is headquartered in Rochester, New York. Bausch & Lomb's 2004 revenues were $2.2 billion; it employs approximately 12,400 people worldwide and its products are available in more than 100 countries. More information about the Company can be found on the Bausch & Lomb Web site at www.bausch.com . Copyright Bausch & Lomb Incorporated.

® / ^TM denote trademarks of Bausch & Lomb Incorporated.